Lupin secures USFDA’s approval for Armlupeg6 mg/0.6 mL injection

01 Dec 2025 Evaluate

Lupin has secured United States Food and Drug Administration’s (USFDA) approval for its Armlupeg (pegfilgrastim-unne) 6 mg/0.6 mL injection for subcutaneous use in a single-dose prefilled syringe, as biosimilar to Neulasta (pegfilgrastim) 6 mg/0.6 mL injection. The product will be manufactured at the company’s Biotech facility in Pune, which was inspected by the USFDA prior to approval. Armlupeg is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. It is also indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2151.70 -13.35 (-0.62%)
23-Jan-2026 10:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1630.70
Dr. Reddys Lab 1245.70
Cipla 1379.80
Zydus Lifesciences 891.50
Lupin 2151.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×